Escort Health with Technology

In 2023, Jiangsu Province welcomed the emergence of a potential unicorn enterprise in the field of ultrasound. Founded by a team comprising seasoned scientists in the ultrasound domain, cardiologists, and serial entrepreneurs, the company is headquartered in Nanjing, China. It operates R&D centers in both China and the United States. Led by a nationally recognized talent in Class A of key engineering projects (returnee Ph.D.), an international R&D team was assembled. The company collaborates closely with globally renowned clinical teams and top domestic acoustic research institutions. Focusing on technological innovations in ultrasound for cardiac electrophysiology and structural heart diseases, the company integrates imaging, mapping, and ablation energy applications. Its mission is to provide more effective treatments for a wider range of cardiac patients. Currently, the company's R&D pipeline includes 2D intracardiac ultrasound imaging systems, 4D intracardiac ultrasound imaging systems, ultrasound three-dimensional mapping systems, and ultrasound energy therapy systems.

With a 4,800-square-meter R&D and manufacturing center in Nanjing equipped with precision testing and automated production facilities, the company ensures high-quality development and manufacturing processes. Additionally, to facilitate technology exchange and innovation in overseas markets, the company has established an R&D center in Massachusetts, USA.

To date, the company has completed three rounds of financing, exceeding 200 million yuan. In January 2023, its product "Disposable Intracardiac Ultrasound Diagnostic Catheter" passed the special review process of the National Medical Products Administration for innovative medical devices. In November of the same year, it obtained the registration certificate (National Medical Device Registration No. 20233061761), making it the first domestically developed and approved high-end intracardiac ultrasound diagnostic catheter in China. Simultaneously, the company successfully completed the commercialization of the 4D intracardiac ultrasound chipset, becoming the third company globally, after Philips and Johnson & Johnson, to master this core technology.

In the future, TINGSN Technology will remain true to its original aspirations, striving to break the monopoly of foreign capital in the domestic market and surpassing domestic competitors with cutting-edge technology. Its goal is to enable more cardiac patients, including those in underdeveloped regions, to receive effective treatments, thereby becoming an influential Chinese medical device manufacturing brand.